Research programme: wound healing agents - AnaMarAlternative Names: AM 220; Project AM 220 - ColMod
Latest Information Update: 17 Jun 2010
At a glance
- Originator AnaMar Medical
- Developer AnaMar AB
- Mechanism of Action Collagen stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Wounds
Most Recent Events
- 25 Jul 2008 Preclinical development is ongoing
- 25 Jul 2006 Preclinical trials in Wounds in Sweden (Topical)